June Election: FDA Reproductive Health Drugs Panel Holds On To Hager For Second Term
This article was originally published in The Pink Sheet Daily
Plan B OTC opponent Hager reappointed to FDA’s Reproductive Health Drugs Advisory Committee, effective June 30. Hager’s term was renewed for another year after an unusually short previous appointment expired and despite an effort by several House members to block his reappointment.
You may also be interested in...
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
With an unrestricted label and once-daily dosing, rivaroxaban will do battle with Boehringer-Ingelheim's dabigatran, which is dosed twice a day but can claim superior efficacy to warfarin in the atrial fibrillation population.
One Trial Plus Supportive Evidence Is Enough For Hospital-, Ventilator-Acquired Pneumonia Indication, Panel Says
Anti-Infective Drugs Advisory Committee members viewed one-trial as practical means of gaining efficacy data.